ClinicalTrials.gg
Active, not recruitingNCT06289998Updated Apr 4, 2025

Study of Tamibarotene in Patients With ADPKD

A Phase 2 interventional study of Tamibarotene and Placebo in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Rege Nephro Co., Ltd.. Active, not recruiting at 8 sites in Japan. Open to participants aged 26 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Rege Nephro Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
26 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Japan — 1 open to participants now, 2 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Japan.

Planned enrollment
10th of 12
70 · median 155
Started
2023
the only one that year
Phase 2
4 of 16
1 open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
Rege Nephro Co., Ltd.

Among the 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Japan, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 2, and was the 15th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

1 of the 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 26 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Japan, or all of them as a file.
02

Study summary

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • Autosomal dominant polycystic kidney disease
04

Who can participate

Ages eligible
26 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as ADPKD by modified Pei-Ravine
  • (CKD-EPI) is equal to or greater than 60 mL/min/1.73m\^2
  • Patients who are judged to be hard to treat with tolvaptan or who do not wish to be treated with tolvaptan, at the time of obtaining consent
  • Patients with systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg. For patients receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, the dose must be constant for at least 6 weeks before obtaining

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or may be pregnant
  • Nursing mother
  • Females with or male subjects with a fertile partner who is unable to use for the following periods:

    1. Female: From to 2 years after the last administration of the study drug
    2. Male: From informed consent to 6 months after the last administration of the study drug
  • Patients within 12 weeks from the last dose of a drug that affects renal cysts, such as tolvaptan, to the first dose of the study drug
  • Patients with complications of intracranial aneurysm, malignant tumor, uncontrolled diabetes, osteoporosis, uncontrolled dyslipidemia, or abnormal liver function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Tamibarotene Group

    Drug: Tamibarotene

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

  • Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.

  • DrugPlacebo

    Subjects are administrated to placebo in daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Changes in TKV from baseline

    TKV

    Time frame: 52 Week after administration of Investigational Product

Secondary outcomes

  1. Changes in TLV from baseline

    TLV

    Time frame: 52 Week after administration of Investigational Product

  2. Changes in eGFR from baseline

    eGFR

    Time frame: 52 Week after administration of Investigational Product

  3. Incidence of adverse events

    Safety

    Time frame: 1 year

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2024
First posted
Mar 4, 2024
StartActual
Dec 22, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06289998
Lead sponsor
Rege Nephro Co., Ltd.
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Dec 22, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamibarotene

Start the discussion